What is aTyr Pharma, Inc. (ATYR) stock price today?

aTyr Pharma, Inc. (ATYR) is currently trading at $0.25, down 3.56% today.

What is ATYR P/E ratio?

aTyr Pharma, Inc.'s P/E ratio is -0.46. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ATYR return on equity (ROE)?

aTyr Pharma, Inc.'s return on equity (ROE) is -95.59%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is aTyr Pharma, Inc.'s market cap?

aTyr Pharma, Inc. has a market capitalization of $24.14M.

NASDAQ · Biotechnology

aTyr Pharma, Inc. (ATYR) Stock

$0.25 -3.56% NASDAQ: ATYR Healthcare

Valuation

Metric	Value
Price	$0.25
Market Cap	$24.14M
P/E Ratio	-0.46
P/B Ratio	0.58
P/S Ratio	148.21
EPS (TTM)	$-0.40
52-Week High	$1.12
52-Week Low	$0.25
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-95.59%
ROA	-87.08%
ROCE	-109.29%
Gross Margin	-117.55%
Operating Margin	-385.74%
Net Margin	-368.57%
Debt/Equity	0.23
Current Ratio	5.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$10.0M	$0	$0	$0
Operating Profit	$-34.0M	$-46.0M	$-55.0M	$-68.0M	$-78.0M
Net Profit	$-34.0M	$-45.0M	$-50.0M	$-64.0M	$-74.0M
EPS	$-1.77	$-1.60	$-0.94	$-0.86	$-0.80
Op Margin	—	-446.8%	-15557.8%	-28899.6%	-40856.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$116.0M	$96.0M	$121.0M	$97.0M	$94.0M
Total Liabilities	$6.0M	$25.0M	$30.0M	$27.0M	$27.0M
Cash	$2.0M	$10.0M	$23.0M	$11.0M	$11.0M
Borrowings	$1.0M	$12.0M	$15.0M	$13.0M	$12.0M

Latest News

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 GlobeNewswire · Jul 15, 2026 What It Means To Hold Moderna Stock In A Crash Trefis · Jul 13, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026 Atyr Pharma: Q1 Earnings Snapshot Associated Press · May 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-33.0M	$-42.0M	$-33.0M	$-69.0M	$-62.0M
Investing Cash Flow	$-92.0M	$46.0M	$-24.0M	$17.0M	$-5.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-15.0M	$11.0M	$13.0M	$-12.0M	$-1.0M
Free Cash Flow	$-33.0M	$-44.0M	$-37.0M	$-69.0M	$-62.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	-0.40
FCF Yield	-194.67%
Quick Ratio	5.12
Interest Coverage	0.00
Return 1Y	-90.31%
Return 3Y	-72.03%
Return 5Y	-87.88%

Ownership

Insiders Held2.45%

Institutions Held46.47%

Institutions Float Held47.64%

Institutional Holder	Shares	Report Date
FMR, LLC	14,706,843	2026-03-31
Federated Hermes, Inc.	10,509,678	2026-03-31
Blackrock Inc.	6,443,904	2026-03-31
UBS Group AG	3,867,213	2026-03-31
Vanguard Capital Management LLC	3,812,132	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRVAcrivon Therapeutics, Inc.	$1.91	+2.14%	-1.12	$81.75M	0.00%
ALXOALX Oncology Holdings Inc.	$1.25	+5.93%	-1.08	$168.20M	0.00%
CAMPCAMP4 Therapeutics Corporation	$3.77	+1.89%	-1.66	$236.58M	0.00%
DTILPrecision BioSciences, Inc.	$6.72	+4.51%	-2.26	$185.48M	0.00%
HYFTMindWalk Holdings Corp.	$1.50	+4.55%	-5.23	$70.25M	0.00%

About aTyr Pharma, Inc.

aTyr Pharma, Inc. is led by CEO Sanjay S. Shukla, employs 56 people, headquartered in US, publicly traded since 2015.

aTyr Pharma, Inc. (ATYR) stock trades at $0.25 with a market capitalization of $24.14M. The stock is valued at a price-to-earnings (P/E) ratio of -0.46, price-to-book of 0.58, price-to-sales of 148.21. Over the past 52 weeks the stock has ranged between $0.25 and $1.12, and currently trades 77.7% below its 52-week high.

On profitability, aTyr Pharma, Inc. generates a return on equity (ROE) of -95.59%, return on capital employed of -109.29%, an operating margin of -385.74%, a net profit margin of -368.57%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides